Pain Management and Opioids: Balancing Risks and Benefits (2.5 CME)
Recorded On: 07/25/2018
-
Register
- Non-Member - Free!
- Regular Member - Free!
- Retired - Free!
- Early Career Physician - Free!
- Resident - Free!
- Student - Free!
- Associate - Free!
- ASAM Staff - Free!
- International Member - Free!
- Emeritus Member - Free!
- Provisional Member - Free!
- Fellow Member - Free!
- Honorary Member - Free!
- CRT Member - Free!
The misuse of extended-release and long-acting (ER/LA) opioids is a major public health problem. Centers for Disease Control and Prevention reported the following:
- From 2000 to 2015 more than half a million people died from drug overdoses.
- 91 Americans die every day from an opioid overdose.
The CO*RE/ASAM Pain Management and Opioids: Balancing Risks and Benefits addresses the opioid public health crisis. This comprehensive course was developed by renowned experts from Collaborative for REMS Education (CO*RE) and incorporates all six units outlined in FDA blueprint for safe opioid prescribing. The updated course also provides necessary context for safe opioid prescribing by discussing biopsychosocial aspects of pain, the newest clinical guidelines on the treatment of chronic pain, and state policies about prescribing opioids.
Learners will be able to:
- Accurately assess patients with pain for consideration of an opioid trial
- Establish realistic goals for pain management and restoration of function
- Initiate opioid treatment (IR and ER/LA) safely and judiciously, maximizing efficacy while minimizing risks
- Monitor and re-evaluate treatment continuously; discontinue safely when appropriate
- Counsel patients and caregivers about use, misuse, abuse, diversion, and overdose
- Educate patients about safe storage and disposal of opioids
- Demonstrate working knowledge and ability to access general and specific information about opioids, especially those used in your practice.
Edwin A. Salsitz
MD, DFASAM
Dr. Edwin A. Salsitz has been an attending physician in the Mount Sinai Beth Israel , Division of Chemical Dependency, New York City, since 1983, and is an Assistant Professor of Psychiatry at the Mount Sinai School of Medicine. He is the principal investigator of the Methadone Medical Maintenance (office-based methadone maintenance) research project.
Dr. Salsitz is certified by the American Board of Addiction Medicine (ABAM), as well as by the Board of Internal Medicine and Pulmonary Disease. He has published and lectures frequently on addiction medicine topics.Dr. Salsitz is a course director for ASAM sponsored buprenorphine trainings,and is a mentor in the PCSS-MAT mentoring program. He has co-chaired the ASAM Review Course, the ASAM Common Threads Course, the ASAM State of the Art course and is a reviewer for the Journal of Addiction Medicine and Drug and Alcohol Dependence. He is the chair of the ASAM REMS course on safe and effective prescribing of opioids.
Dr. Salsitz was the Co-chair of the ASAM CME committee and Chair of the New York Society of Addiction Medicine CME and Education committee. Dr. Salsitz is a member of the medical advisory panel, for the New York State Office of Alcohol and Substance Abuse Services. Dr. Salsitz is the recipient of the 2014 ASAM Annual Award, and the 2018 ASAM Annual Educator of the Year Award.
CME Information and Disclosure Listing
The American Society of Addiction Medicine (ASAM) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to sponsor continuing medical education for physicians. ASAM has been awarded the highest level of Accreditation with Commendation by the ACCME as a provider of continuing medical education.
The American Society of Addiction Medicine designates this live activity for a maximum of 2.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
In accordance with the disclosure policies of the American Society of Addiction Medicine (ASAM) and the Accreditation Council for Continuing Medical Education (ACCME), the effort is made to ensure balance, independence, objectivity, and scientific rigor in all educational activities. These policies include resolving all conflicts of interest between the Medical Education Council, the CME Committee, program planning committees and faculty, and commercial interests that might otherwise compromise the goal and educational integrity of the activity. All program planning committee members and faculty participating in the activity have disclosed all relevant financial relationships with commercial interests. The ASAM CME Committee has reviewed these disclosures and determined that the program planning committee and faculty relationships are not inappropriate in the context of their respective presentations and are not inconsistent with the educational goals and integrity of the activity.
ASAM CME Committee
| Name | Nature of Relevant Financial Relationship | ||
| Commercial Interest | What was received? | For what role? | |
| Catherine R. Friedman, MD, FAPA, DFASAM, Chair | None |
|
|
| R. Jeffrey Goldsmith, MD, DLFAPA, DFASAM | None |
|
|
| Adam J. Gordon, MD, MPH, FACP, DFASAM, CMRO | None |
|
|
| Zwaantje Hamming, FNP-C, CARN-AP | None |
|
|
| Noel Ilogu, MD, MRCP, DFASAM | None |
|
|
| Hebert L. Malinoff, MD, FACP, DFASAM | None |
|
|
| Edwin A. Salsitz, MD, DFASAM | None |
|
|
| ASAM Staff and Consultants: |
|
|
|
| Arlene C. Deverman, MA, CAE, CFRE | None |
|
|
| Marcia Jackson PhD | None |
|
|
| Sandy Metcalfe | None |
|
|
Program Planning Committee
Faculty
| Name | Nature of Relevant Financial Relationship | ||
| Commercial Interest | What was received? | For what role? | |
| Herbert Malinoff, MD, FACP, DFASAM | None |
|
|
| Yngvild Olsen, MD, MPH | None |
|
|
| Theodore Parran, MD, FACP | None |
|
|
| Edwin Salsitz, MD, DFASAM | None |
|
|
| R. Corey Waller, MD, MS, FACEP | None |
|
|
| Name | Nature of Relevant Financial Relationship | ||
| Commercial Interest | What was received? | For what role? | |
| Edwin A. Salsitz, MD, DFASAM | None |
|
|
ASAM CME Committee Reviewers
ASAM Medical Education Council| Name | Nature of Relevant Financial Relationship | ||
| Commercial Interest | What was received? | For what role? | |
| Jacob Bobrowski, MD, FAAFP | None |
|
|
| Anthony H. Dekker, DO, DFASAM | None |
|
|
| Name | Nature of Relevant Financial Relationship | ||
| Commercial Interest | What was received? | For what role? | |
| Peter Selby, MBBS, CCFP, FCFP, MHSc, DipABAM, DFASAM, Chair | Pfizer Johnson & Johnson Pfizer Canada | Grant funding Consulting Fees Consulting Fees | Principal Investigator Consulting Consulting |
| Daniel Alford, MD, MPH | None |
|
|
| Michael Fingerhood, MD, FACP, FASAM | None |
|
|
| Catherine R. Friedman, MD, FAPA, DFASAM | None |
|
|
| Adam J. Gordon, MD, MPH, FACP, DFASAM, CMRO | None |
|
|
| Miriam S. Komaromy, MD, FACP, DFASAM | None |
|
|
| Edwin A. Salsitz, MD, DFASAM | None |
|
|
| Mark P. Schwartz, MD, DFASAM | None |
|
|
| Mark A. Weiner, MD, FASAM | None |
|
|
| ASAM Staff and Consultants: |
|
|
|
| Arlene C. Deverman, MA, CAE, CFRE | None |
|
|
| Marcia Jackson PhD | None |
|
|
| Jennifer L. Butchart | None |
|
|
| Penny S. Mills, MBA | None |
|
|
ACCME Accreditation Statement
The American Society of Addiction Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
AMA Credit Designation Statement
The American Society of Addiction Medicine designates this enduring material for a maximum of 2.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
ABPM Maintenance of Certification (MOC)
The American Board of Preventive Medicine (ABPM) has approved this activity for a maximum of 2.5 LLSA credits towards ABPM MOC Part II requirements.
ABAM Transitional Maintenance of Certification (tMOC)
This course has been approved by the American Board of Addiction Medicine (ABAM). Physicians enrolled in the ABAM Transitional Maintenance of Certification Program (tMOC) can apply a maximum of 2.5 AMA PRA Category 1 Credit(s)™ for completing this course.
Acknowledgement
Presented by ASAM, a member of the Collaborative on REMS Education (CO*RE), 10 interdisciplinary organizations working together to improve pain management and prevent adverse outcomes.
RPC Commercial Support Disclosure Statement
This educational activity is supported by an independent educational grant from the ER/LA Opioid Analgesic REMS Program Companies. Please see this link for a listing of the member companies. This activity is intended to be fully compliant with the ER/LA Opioid Analgesic REMS education requirements issued by the US Food & Drug Administration.
This course is not intended to advocate for the use of ER/LA Opioids, but to ensure proper education about safe prescribing practices should a medical provider determine that ER/LA Opioids are the best course of treatment.
Key:
Complete
Next
Failed
Available
Locked